← Oncology Approval Tracker

FDA DECISION ·

Enhertu

fam-trastuzumab deruxtecan-nxki · Daiichi Sankyo

Accelerated approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable or metastatic NSCLC with an activating HER2 (ERBB2) mutation on an FDA-approved test after prior systemic therapy.

LAMPGEN ANALYSIS

Why it matters

This lung cancer action is based on activating HER2 mutations rather than breast cancer HER2 expression thresholds.

What research teams should watch

Verify the mutation report and prior systemic treatment. Document lung symptoms and escalation plans during follow-up.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Biomarker-selected advanced NSCLC

PRIMARY RECORDS

Sources